StockTipsArenaBeta

BUY Aurobindo Pharma — Vikas Salunkhe, Nirmal Bang Securities

BUYAurobindo Pharma
Aurobindo Pharma share price target & all analyst calls

byVikas Salunkhe, Nirmal Bang SecuritiesHorizon: NA (inferred Swing (≤2wk))25 Jun 2026via CNBC Awaaz.

Entry₹1,540Stated
Target₹1,610
Total upside +4.55% (call closed)
Stop loss₹1,510-1.95% risk
Exit₹1,6103 Jul 2026, 10:00 am
Target hit+4.55%0.00%upside left
Follow Vikas Salunkhe for new calls(27% target hit, 130 closed calls)Get alertsWatch AUROPHARMA for new buy/sell callsGet alertsSee 1 active Swing call on AUROPHARMASee 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 25 Oct, 10:47 pm IST
7 supporting0 opposing
Supports the BUY call (7)

Aurobindo Pharma USA Inc., a subsidiary of Aurobindo Pharma, has completed the acquisition of Lannett.

NSE · Acquisition·30 Jun · 3d ago

(opens in new tab)

Aurobindo Pharma Ltd has announced the completion of an acquisition.

BSE · Company Update·25 Jun · 1w ago

(opens in new tab)

Aurobindo Pharma has completed the execution of a solar power purchase agreement and acquired a 26% stake in Swarnaakshu Solar Power Private Limited for Rs. 52 lakhs. The company plans further investm

NSE · Acquisition·25 Jun · 1w ago

(opens in new tab)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·23 Jun · 1w ago

Aurobindo Pharma USA has received approval from the FTC to acquire Lannett Company, a significant strategic move for the company.

NSE · Press Release·22 Jun · 2w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Vikas Salunkhe, Nirmal Bang Securities

Every call and its outcome